Effect of Naltrexone in Achieving and Maintaining Abstinence From Alcohol in Patients With Cirrhosis.

Not Applicable

Completed

• Conditions: Liver Cirrhosis
• Interventions: Drug: Placebo oral tablet; Drug: Naltrexone

• Registration Number: NCT04391764
• Lead Sponsor: Institute of Liver and Biliary Sciences, India

Brief Summary

The aim of the study is to study the safety and tolerability of Naltrexone in patients with Alcohol liver disease over a 12 week duration without liver related side effects. The project will be conducted at ILBS from March 2020 to February 2021. The concept is to estimate the usage of naltrexone and establish its safety in cirrhotics and study its effect on achieving and maintaining abstinence and in reducing lapses and relapses. Thereby reducing the progression of alcoholic liver disease as continued ethanol consumption is an important predictor in increasing overall morbidity and mortality.

All ALD patients will be included as per inclusion and exclusion criteria, after taking informed consent from the patient or their relatives. In case of any reactions, the drug will be stopped as per the study stopping rule.

After following the inclusion and exclusion criteria, ALD patients will be recruited into the study. It's a double blind RCT, hence both the patient and the investigator will be blinded and the drug will be issued by the trial co-ordinator after taking informed written consent and explaining the side effects. Naltrexone at a dose of 50 mg per day and placebo are included in the tablets. Placebo tablets will be identical in size, colour, shape, and taste. Naltrexone tablets will be entrusted to a family member to administer every dose and monitor for side effects.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2020-05-08
• Study First Submitted QC: 2020-05-15
• Study First Posted: 2020-05-18
• Study Start: 2020-12-06
• Primary Completion: 2022-10-31
• Study Completion: 2022-10-31
• Status Verified: 2023-03
• Last Update Submitted: 2023-03-27
• Last Update Posted: 2023-03-28

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

1. All consecutive alcohol dependent cirrhotic aged between 18-60 yrs.
2. Fulfilling DSM - 5 criteria for alcohol use disorder (Association, 2013).

Read More

Exclusion Criteria

1. Current Hepatic Encephalopathy
2. Total Bilirubin > 3 mg/dl.
3. Recent bleed.
4. Treatment with corticosteroids within the past 60 days.
5. Unwilling to participate.
6. Dependence on any other substance (except Nicotine).
7. Psychotic disorder requiring treatment/Suicidal tendency.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo oral tablet	Placebo tablets will be identical in size, colour, shape, and taste and will be given in a similar manner.
Naltrexone	Naltrexone	Naltrexone at a dose of 50 mg per day.

Primary Outcome Measures

Name	Time	Method
Proportion of patients achieving and maintaining alcohol abstinence at 12 weeks in both groups	12 weeks

Secondary Outcome Measures

Name	Time	Method
Proportion of patients on Naltrexone without liver related adverse effects as compared to placebo	12 weeks
difference in craving measures between groups at 4 weeks in both groups	4 weeks	OCDS (Obsessive-Compulsive Drinking Scale) scale will be use to measure the craving
Proportion of patients maintaining abstinence from alcohol at 12 months in both groups	12 months
difference in craving measures between both groups at 8 weeks.	8 weeks	OCDS (Obsessive-Compulsive Drinking Scale) scale will be use to measure the craving
difference in craving measures between both groups at 12 weeks.	12 weeks	OCDS (Obsessive-Compulsive Drinking Scale) scale will be use to measure the craving
difference in craving measures between both groups at 12 months.	12 months	OCDS (Obsessive-Compulsive Drinking Scale) scale will be use to measure the craving
Proportion of patients maintaining abstinence from alcohol at 6 months in both groups	6 months
difference in craving measures between both groups at 6 months.	6 months	OCDS (Obsessive-Compulsive Drinking Scale) scale will be use to measure the craving

Trial Locations

Locations (1)

Institute of Liver and Biliary Sciences; 🇮🇳 New Delhi, Delhi, India